Luteolin Inhibits Human Keratinocyte Activation and Decreases NF-κB Induction That Is Increased in Psoriatic Skin
Open Access
- 28 February 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (2) , e90739
Abstract
Psoriasis (Ps) is an autoimmune disease characterized by keratinocyte hyperproliferation and chronic inflammation, with increased expression of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF). Anti-TNF biologic agents are effective in treating Ps, but are associated with increased risk of infections and blood malignancies. Moreover, keratinocyte hyperproliferation and activation have yet to be addressed. Flavonoids, such as luteolin, are natural compounds with potent anti-inflammatory properties, but their actions on keratinocytes remain unknown. We show that TNF (50 ng/mL) triggers significant production of inflammatory mediators interleukin-6, interleukin-8 and VEGF from both human HaCaT and primary keratinocytes. Pretreatment with the flavonoid luteolin (10–100 µM) significantly inhibits mRNA expression and release of all three mediators in a concentration-dependent manner. More importantly, luteolin decreases TNF-induced phosphorylation, nuclear translocation and DNA binding of the nuclear factor-kappa B (NF-κB) typically involved in inflammatory mediator transcription. We also report that luteolin reduces TNF-induced mRNA expression of two genes (NFKB1 and RELA) encoding two NF-κB subunits (NF-κB p50 and NF-κB p65, respectively). Interestingly, we show that gene expression of RELA is increased in human psoriatic skin. Keratinocyte proliferation, which is a characteristic feature of psoriatic skin, is effectively reduced by luteolin in HaCaT cells, but not in primary keratinocytes. Finally, luteolin does not affect intracellular ATP production or viability. Appropriate formulations of luteolin and related flavones may be promising candidates to be developed into local and systemic treatments for Ps and other inflammatory skin diseases.Keywords
This publication has 52 references indexed in Scilit:
- Dopamine Agonists Upregulate IL-6 and IL-8 Production in Human KeratinocytesNeuroimmunomodulation, 2012
- Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolinJournal of Neuroinflammation, 2012
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Quercetin Is More Effective than Cromolyn in Blocking Human Mast Cell Cytokine Release and Inhibits Contact Dermatitis and Photosensitivity in HumansPLOS ONE, 2012
- Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: Relevance to atopic dermatitisJournal of Allergy and Clinical Immunology, 2011
- NEMO and RIP1 Control Cell Fate in Response to Extensive DNA Damage via TNF-α Feedforward SignalingCell, 2011
- Dose- and time-dependent effects of luteolin on carbon tetrachloride-induced hepatotoxicity in miceExperimental and Toxicologic Pathology, 2009
- PsoriasisNew England Journal of Medicine, 2009
- Luteolin inhibits myelin basic protein‐induced human mast cell activation and mast cell‐dependent stimulation of Jurkat T cellsBritish Journal of Pharmacology, 2008
- PsoriasisNew England Journal of Medicine, 2005